Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate

Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from baseline after 36 weeks of treatment.
After 36 weeks of treatment, patients receiving sparsentan achieved a mean reduction in proteinuria from a baseline of 49.8%, compared to 15.1% for irbesartan-treated patients.
Preliminary estimated glomerular filtration rate (eGFR) data indicate a potentially clinically meaningful treatment effect after two years of treatment.
Topline results from the confirmatory endpoint analysis are expected in 2H of 2023.
Travere Therapeutics remains on track to provide a regulatory update on its Phase 3 DUPLEX Study of sparsentan for focal segmental glomerulosclerosis (FSGS) treatment during Q3 of 2021.
The Company plans to apply for accelerated approval in the U.S. in 1H of 2022. Also, it intends to apply for conditional marketing authorization in Europe.
Price Action: TVTX shares are up 13.7% at $17.56 during the premarket session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.